title: Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells.
abstract: Chronic regional pain syndrome (CRPS) can be intractable to treat and patients sometimes suffer for many years. Therefore, new treatment strategies are needed to alleviate symptoms in CRPS patients. This case report describes a patient suffering from intractable CRPS type 1 for 13 years. Due to her swollen painful feet and left knee she is wheelchair-bound. The combination of palmitoylethanolamide and ketamine 10% cream reduced her pain by more than 50% after 1 month of treatment, and a marked reduction in swelling and skin discoloration was noticed. Furthermore, she could walk independently again and she experienced no side effects. Thus, palmitoylethanolamide and topical ketamine could be a combination therapy option for treating CRPS patients.
authors: Institute for Neuropathic Pain, Bosch en Duin, The Netherlands;
authors: Jan M
authors: JM
authors: Keppel Hesselink
authors: David J
authors: DJ
authors: Kopsky
keywords: CRPS; cream; endocannabinoid; ketamine; mast cells; palmitoylethanolamide; sudeck
references: Biochem Pharmacol. 2011 Aug 15;82(4):380-8
references: 21601562
references: Br J Pharmacol. 2002 Oct;137(4):413-20
references: 12359622
references: PLoS One. 2011;6(10):e26823
references: 22046372
references: Br J Pharmacol. 2001 Aug;133(8):1263-75
references: 11498512
references: Minerva Med. 2011 Apr;102(2):141-7
references: 21483401
references: Br J Pharmacol. 2000 Jan;129(2):227-30
references: 10694225
references: Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3739-43
references: 8170980
references: J Neuroinflammation. 2012 Mar 09;9:49
references: 22405189
references: Biochimie. 2010 Jun;92(6):724-7
references: 20096327
references: Anesth Analg. 2003 Oct;97(4):1108-1116
references: 14500166
references: Mol Interv. 2007 Feb;7(1):26-41
references: 17339604
references: Autoimmun Rev. 2013 Apr;12(6):682-6
references: 23219953
references: Pain Med. 2012 Sep;13(9):1121-30
references: 22845893
references: Vet Immunol Immunopathol. 2010 Jan 15;133(1):9-15
references: 19625089
references: J Mol Med (Berl). 2007 May;85(5):523-30
references: 17396241
references: Br J Pharmacol. 2002 Jun;136(3):452-8
references: 12023948
references: Mol Pain. 2011 Jun 03;7:42
references: 21639869
references: J Neuroimmune Pharmacol. 2013 Jun;8(3):547-63
references: 23188523
references: Life Sci. 2005 Aug 19;77(14):1685-98
references: 15963531
references: CNS Neurol Disord Drug Targets. 2012 May;11(3):191
references: 22483302
references: Mediators Inflamm. 2002 Feb;11(1):47-51
references: 11930962
references: J Orofac Pain. 2012 Spring;26(2):99-104
references: 22558609
references: Pain. 2009 Nov;146(1-2):18-25
references: 19703730
references: Anesthesiology. 2012 Apr;116(4):882-95
references: 22343473
references: Mediators Inflamm. 2006;2006(1):28398
references: 16864900
references: ISRN Surg. 2011;2011:917350
references: 22084787
references: CNS Neurol Disord Drug Targets. 2011 Dec;10(8):916-20
references: 22229320
references: Can J Anaesth. 2010 Feb;57(2):149-66
references: 20054678
references: Eur J Neurosci. 2008 Aug;28(4):633-41
references: 18657182
references: Immunol Lett. 2004 Feb 15;91(2-3):147-54
references: 15019283
references: Prostaglandins Other Lipid Mediat. 2009 Sep;89(3-4):105-11
references: 19615459
references: Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3312-25
references: 23108549
references: Mol Pharmacol. 2005 Jan;67(1):15-9
references: 15465922
references: Pain Pract. 2012 Feb;12(2):148-53
references: 21676162
references: J Pain Symptom Manage. 2004 Feb;27(2):101-3
references: 15157033
references: Case Rep Med. 2012;2012:471835
references: 22851976
references: Anesthesiology. 2010 Sep;113(3):713-25
references: 20693883
references: J Pain Symptom Manage. 2010 Feb;39(2):e9-e10
references: 20152584
references: Shock. 2012 Oct;38(4):356-66
references: 22772472
references: Eur J Pharmacol. 2001 May 11;419(2-3):191-8
references: 11426841
references: Mini Rev Med Chem. 2013 Feb;13(2):237-55
references: 22697514
references: J Neurosci. 2003 Aug 27;23(21):7767-75
references: 12944505
references: Eur J Pain. 2013 Feb;17(2):158-73
references: 23042687
references: Eur J Pharmacol. 1996 Apr 11;300(3):227-36
references: 8739213
references: Neurobiol Dis. 2009 Jan;33(1):57-71
references: 18930143
references: Biochim Biophys Acta. 1999 Sep 22;1440(2-3):266-74
references: 10521710
references: Neuropharmacology. 2005 Jun;48(8):1154-63
references: 15910891
references: Br J Pharmacol. 2013 Mar;168(6):1430-44
references: 23083124
references: Br J Pharmacol. 2012 Jun;166(4):1474-89
references: 22321194
references: Pain. 2008 Oct 31;139(3):541-550
references: 18602217
references: Lancet. 1993 Oct 23;342(8878):1012-6
references: 8105263
references: Brain Behav Immun. 2012 Feb;26(2):311-7
references: 22019552
references: Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3376-80
references: 7724569
references: Biochim Biophys Acta. 1998 Jan 15;1389(2):101-11
references: 9461251
references: Nature. 1998 Jul 16;394(6690):277-81
references: 9685157
references: J Pain Res. 2012;5:437-42
references: 23166447
references: Case Rep Med. 2011;2011:319750
references: 22028723
references: Brain Res. 2008 Aug 21;1226:8-17
references: 18621360
references: Neuroscientist. 2009 Oct;15(5):450-63
references: 19826169
references: Pain Med. 2009 Jul;10 Suppl 2:S53-66
references: 19691685
references: Pain. 2008 Jul 31;137(3):507-519
references: 18035493
references: Eur J Pharmacol. 2000 Aug 4;401(2):121-30
references: 10924916
references: J Neurosci. 2012 Sep 12;32(37):12735-43
references: 22972997
references: Biochem Biophys Res Commun. 2012 Aug 24;425(2):237-43
references: 22828511